These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 32335928)

  • 1. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.
    Hamadeh F; MacNamara SP; Aguilera NS; Swerdlow SH; Cook JR
    Mod Pathol; 2015 Apr; 28(4):564-74. PubMed ID: 25216226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
    Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
    J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
    Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
    Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
    Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
    Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
    Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
    Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
    Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP
    Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
    Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
    Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
    Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
    Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significances of MYD88
    Meng Q; Cao XX; Li J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature.
    Bassarova A; Trøen G; Spetalen S; Micci F; Tierens A; Delabie J
    Am J Clin Pathol; 2015 Jun; 143(6):797-806. PubMed ID: 25972321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
    Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
    Amaador K; Vos JMI; Pals ST; Kraan W; Dobber JA; Minnema MC; Koene HR; de Bruin PC; Zwinderman AH; Kersten MJ
    Leuk Lymphoma; 2022 May; 63(5):1070-1079. PubMed ID: 34961399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.